journal
MENU ▼
Read by QxMD icon Read
search

Liver Cancer

journal
https://www.readbyqxmd.com/read/27781202/selective-internal-radiation-therapy-sirt-as-conversion-therapy-for-unresectable-primary-liver-malignancies
#1
REVIEW
Alessandro Cucchetti, Alberta Cappelli, Giorgio Ercolani, Cristina Mosconi, Matteo Cescon, Rita Golfieri, Antonio Daniele Pinna
BACKGROUND: Many patients with primary liver cancers are not candidates for surgery, and systemic therapies are seldom effective. Selective internal radiation therapy (SIRT) has been shown to obtain partial and even complete response in unresectable primary tumors. As a "side effect", SIRT can induce contra-lateral liver hypertrophy. Tumor response to SIRT can be sufficient to allow disengagement from normal vital structures whose involvement is the cause of the initial unresectability...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781201/molecular-pathogenesis-of-hepatocellular-carcinoma
#2
Daniel Wai-Hung Ho, Regina Cheuk-Lam Lo, Lo-Kong Chan, Irene Oi-Lin Ng
The pathogenesis of hepatocellular carcinoma (HCC) is a multistep process involving the progressive accumulation of molecular alterations pinpointing different molecular and cellular events. The next-generation sequencing technology is facilitating the global and systematic evaluation of molecular landscapes in HCC. There is emerging evidence supporting the importance of cancer metabolism and tumor microenvironment in providing a favorable and supportive niche to expedite HCC development. Moreover, recent studies have identified distinct surface markers of cancer stem cell (CSC) in HCC, and they also put forward the profound involvement of altered signaling pathways and epigenetic modifications in CSCs, in addition to the concomitant drug resistance and metastasis...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781200/is-surgical-resection-justified-for-advanced-intrahepatic-cholangiocarcinoma
#3
Tomoaki Yoh, Etsuro Hatano, Kenya Yamanaka, Takahiro Nishio, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto
BACKGROUNDS: Prognosis for patients with advanced intrahepatic cholangiocarcinoma (ICC) with intrahepatic metastasis (IM), vascular invasion (VI), or regional lymph node metastasis (LM) remains poor. The aim of this study was to clarify the indications for surgical resection for advanced ICC. METHODS: We retrospectively divided 213 ICC patients treated at Kyoto University Hospital between 1993 and 2013 into a resection (n=164) group and a non-resection (n=49) group...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781199/feasibility-of-extracted-overlay-fusion-imaging-for-intraoperative-treatment-evaluation-of-radiofrequency-ablation-for-hepatocellular-carcinoma
#4
Yuki Makino, Yasuharu Imai, Takumi Igura, Sachiyo Kogita, Yoshiyuki Sawai, Kazuto Fukuda, Takayuki Iwamoto, Junya Okabe, Manabu Takamura, Norihiko Fujita, Masatoshi Hori, Tetsuo Takehara, Masatoshi Kudo, Takamichi Murakami
BACKGROUND AND AIMS: Extracted-overlay fusion imaging is a novel computed tomography/magnetic resonance-ultrasonography (CT/MR-US) imaging technique in which a target tumor with a virtual ablative margin is extracted from CT/MR volume data and synchronously overlaid on US images. We investigated the applicability of the technique to intraoperative evaluation of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). METHODS: This retrospective study analyzed 85 HCCs treated with RFA using extracted-overlay fusion imaging for guidance and evaluation...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781198/novel-pretreatment-scoring-incorporating-c-reactive-protein-to-predict-overall-survival-in-advanced-hepatocellular-carcinoma-with-sorafenib-treatment
#5
Hiroyuki Nakanishi, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Mayu Higuchi, Tsubasa Yoshida, Yasuyuki Komiyama, Kenta Takaura, Tsuguru Hayashi, Konomi Kuwabara, Natsuko Nakakuki, Hitomi Takada, Masako Ueda, Nobuharu Tamaki, Shoko Suzuki, Jun Itakura, Yuka Takahashi, Namiki Izumi
OBJECTIVES: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. METHODS: A total of 165 patients with advanced HCC who were treated with sorafenib were analyzed. Readily available baseline factors were used to establish a scoring system for the prediction of survival. RESULTS: The median survival time (MST) was 14.2 months. The independent prognostic factors were C-reactive protein (CRP) <1...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781197/surgery-for-intermediate-and-advanced-hepatocellular-carcinoma-a-consensus-report-from-the-5th-asia-pacific-primary-liver-cancer-expert-meeting-apple-2014
#6
Ming-Chih Ho, Kiyoshi Hasegawa, Xiao-Ping Chen, Hiroaki Nagano, Young-Joo Lee, Gar-Yang Chau, Jian Zhou, Chih-Chi Wang, Young Rok Choi, Ronnie Tung-Ping Poon, Norihiro Kokudo
BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy does not recommended surgery for treating BCLC stage B and C hepatocellular carcinoma (HCC). However, numerous Asia-Pacific institutes still perform surgery for this patient group. This consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting aimed to share opinions and experiences pertaining to liver resection for intermediate and advanced HCCs and to provide evidence to issue recommendations for surgery in this patient group...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27781196/regorafenib-as-second-line-systemic-therapy-may-change-the-treatment-strategy-and-management-paradigm-for-hepatocellular-carcinoma
#7
EDITORIAL
https://www.readbyqxmd.com/read/27493897/personalized-clinical-trials-in-hepatocellular-carcinoma-based-on-biomarker-selection
#8
REVIEW
Bingnan Zhang, Richard S Finn
BACKGROUND: Since the approval of sorafenib there have been numerous failures of new agents in Phase III studies for treatment of advanced hepatocellular carcinoma (HCC). These studies have generally ignored the molecular heterogeneity of HCC and they have not enrolled patients based on predictive markers of response. The development of molecular targeted therapeutics in HCC needs to model the approach that has been taken with great success in other solid tumors, to decrease the likelihood of failure in future studies...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493896/how-to-improve-therapeutic-ratio-in-radiotherapy-of-hcc
#9
REVIEW
Chiao-Ling Tsai, Feng-Ming Hsu, Jason Chia-Hsien Cheng
BACKGROUND: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT). SUMMARY: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493895/liver-directed-radiotherapy-for-hepatocellular-carcinoma
#10
REVIEW
Florence K Keane, Jennifer Y Wo, Andrew X Zhu, Theodore S Hong
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) continues to increase world-wide. Many patients present with advanced disease with extensive local tumor or vascular invasion and are not candidates for traditionally curative therapies such as orthotopic liver transplantation (OLT) or resection. Radiotherapy (RT) was historically limited by its inability to deliver a tumoricidal dose; however, modern RT techniques have prompted renewed interest in the use of liver-directed RT to treat patients with primary hepatic malignancies...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493894/survival-analysis-over-28-years-of-173-378-patients-with-hepatocellular-carcinoma-in-japan
#11
Masatoshi Kudo, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi
BACKGROUND: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. METHODS: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493893/survival-benefit-of-locoregional-treatment-for-hepatocellular-carcinoma-with-advanced-liver-cirrhosis
#12
Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC. METHODS: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493892/consensus-for-radiotherapy-in-hepatocellular-carcinoma-from-the-5th-asia-pacific-primary-liver-cancer-expert-meeting-apple-2014-current-practice-and-future-clinical-trials
#13
Hee Chul Park, Jeong Il Yu, Jason Chia-Hsien Cheng, Zhao Chong Zeng, Ji Hong Hong, Michael Lian Chek Wang, Mi Sook Kim, Kwan Hwa Chi, Po-Ching Liang, Rheun-Chuan Lee, Wan-Yee Lau, Kwang Hyub Han, Pierce Kah-Hoe Chow, Jinsil Seong
A consensus meeting to develop practice guidelines and to recommend future clinical trials for radiation therapy (RT), including external beam RT (EBRT), and selective internal RT (SIRT) in hepatocellular carcinoma (HCC) was held at the 5th annual meeting of the Asia-Pacific Primary Liver Cancer Expert consortium. Although there is no randomized phase III trial evidence, the efficacy and safety of RT in HCC has been shown by prospective and retrospective studies using modern RT techniques. Based on these results, the committee came to a consensus on the utility and efficacy of RT in the management of HCC according to each disease stage as follows: in early and intermediate stage HCC, if standard treatment is not compatible, RT, including EBRT and SIRT can be considered...
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27493891/risk-of-hepatocellular-carcinoma-in-patients-with-hepatitis-c-virus-who-achieved-sustained-virological-response
#14
M Kudo
No abstract text is available yet for this article.
July 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386432/optimal-selection-of-radiotherapy-as-part-of-a-multimodal-approach-for-hepatocellular-carcinoma
#15
REVIEW
Hong In Yoon, Jinsil Seong
A multimodal approach to treatment is a basic oncologic principle with proven survival benefits for most cancer types. However, existing guidelines recommend single modalities for treating each stage of hepatocellular carcinoma (HCC). Nonetheless, multimodal approaches can be considered for HCC, depending on the characteristics of the disease in individual cases. Radiotherapy (RT), an effective local modality, is a critical element of most multimodal approaches. Improved RTtechnology and increased understanding of the tolerance of the liver to radiation have contributed to the popularity of RT for treating liver tumors in clinical practice...
April 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386431/tumor-heterogeneity-in-hepatocellular-carcinoma-facing-the-challenges
#16
REVIEW
Li-Chun Lu, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng
Tumor heterogeneity in hepatocellular carcinoma (HCC), such as that found in second primary tumors after curative treatment, synchronous multifocal tumors of different clonality, or intratumor heterogeneity, poses severe challenges for the development and administration of systemic molecular targeted therapies. Various methodologies, including historical DNA ploidy analysis, integrated hepatitis B virus DNA analysis, DNA fingerprinting, and next-generation sequencing technologies, are used to explore tumor heterogeneity in HCC...
April 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386430/selection-criteria-and-current-issues-in-liver-transplantation-for-hepatocellular-carcinoma
#17
REVIEW
Toshimi Kaido
Liver transplantation (LT) is an ideal treatment for hepatocellular carcinoma (HCC) because it not only resects HCCs but it also replaces the underlying damaged liver with normal tissue. However, the selection criteria are still a matter of debate. After the introduction of the Milan criteria, some expanded criteria focusing on tumor size and number have been proposed. In addition, new expanded criteria considering tumor biology have been proposed using tumor markers and (18)F-fluorodeoxyglucose positron emission tomography...
April 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386429/outcomes-of-hepatic-resection-in-intrahepatic-cholangiocarcinoma-patients-with-diabetes-hypertension-and-dyslipidemia-significance-of-routine-follow-up
#18
Takayoshi Nishioka, Shoji Kubo, Shogo Tanaka, Kenichi Wakasa, Shigekazu Takemura, Masahiko Kinoshita, Genya Hamano, Yuko Kuwae, Toshihiko Shibata, Shigefumi Suehiro
BACKGROUND: The outcomes of hepatic resection in intrahepatic cholangiocarcinoma (ICC) patients with diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL) (metabolic components) remain unclear. METHODS: The outcomes of 43 ICC patients without known risk factors for ICC who underwent hepatic resection were retrospectively reviewed. These patients were divided into three groups: those followed-up for metabolic components at least every 6 months (follow-up group, n=16), those not followed-up for metabolic components (no follow-up group, n=14), and those without metabolic components (control group, n=13)...
April 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386428/national-cancer-centre-singapore-consensus-guidelines-for-hepatocellular-carcinoma
#19
Pierce K H Chow, Su Pin Choo, David C E Ng, Richard H G Lo, Michael L C Wang, Han Chong Toh, David W M Tai, Brian K P Goh, Jen San Wong, Kiang Hiong Tay, Anthony S W Goh, Sean X Yan, Kelvin S H Loke, Sue Ping Thang, Apoorva Gogna, Chow Wei Too, Farah Gillian Irani, Sum Leong, Kiat Hon Lim, Choon Hua Thng
Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world, but the second most common cause of cancer death. There is no universally accepted consensus practice guidelines for HCC owing to rapid developments in new treatment modalities, the heterogeneous epidemiology and clinical presentation of HCC worldwide. However, a number of regional and national guidelines currently exist which reflect practice relevant to the epidemiology and collective experience of the consensus group. In 2014, clinicians at the multidisciplinary Comprehensive Liver Cancer Clinic (CLCC) at the National Cancer Centre Singapore (NCCS) reviewed the latest published scientific data and existing international and regional practice guidelines, such as those of the National Comprehensive Cancer Network, American Association for the Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver, and modified them to reflect local practice...
April 2016: Liver Cancer
https://www.readbyqxmd.com/read/27386427/heterogeneity-and-subclassification-of-barcelona-clinic-liver-cancer-stage-b
#20
M Kudo
No abstract text is available yet for this article.
April 2016: Liver Cancer
journal
journal
47850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"